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Abstract
Background: Clinical guidelines have been the subject of much criticism in primary care literature partly due to
potential conflicts in their implementation among patients with multiple chronic conditions. We assessed the
relevance of selected Canadian clinical guidelines on chronic diseases for patients with comorbidity and examined
their quality.
Methods: We selected 16 chronic medical conditions according to their frequency of occurrence, complexity of
treatment, and pertinence to primary care. Recent Canadian clinical guidelines (2004 - 2009) on these conditions,
published in English or French, were retrieved. We assessed guideline relevance to the care of patients with
comorbidity with a tool developed by Boyd and colleagues. Quality was assessed using the Appraisal of Guidelines
Research and Evaluation (AGREE) instrument.
Results: Regarding relevance, 56.2% of guidelines addressed treatment for patients with multiple chronic
conditions and 18.8% addressed the issue for older patients. Fifteen guidelines (93.8%) included specific
recommendations for patients with one concurrent condition; only three guidelines (18.8%) addressed specific
recommendations for patients with two comorbid conditions and one for more than two concurrent comorbid
conditions. Quality of the evaluated guidelines was good to very good in four out of the six domains measured
using the AGREE instrument. The domains with lower mean scores were Stakeholder Involvement and Applicability.
Conclusions: The quality of the Canadian guidelines examined is generally good, yet their relevance for patients
with two or more chronic conditions is very limited and there is room for improvement in this respect.
Background
Chronic disease is currently the leading health problem
worldwide and represents an important challenge for
healthcare systems [1]. The proportion of total direct
medical care expenditures devoted to people with
chronic diseases has reached $39 billion a year (2004) in
Canada [2]. All chronic diseases combined are estimated
to account for over 53% of the total economic burden of
illness in Canada [2].
The proportion of patients affected by multiple concur-
rent chronic medical conditions (multimorbidity) is on
the rise [3]. Data from different countries demonstrate
that this situation results in a high burden for primary
care practices where multimorbidity is the rule rather
than the exception [3-7]. A Canadian study that included
980 adult patients consulting in a primary care setting
found that nine out of 10 patients had more than one
chronic condition, and approximately 50% had five or
more [4].
Clinical guidelines aim to improve the quality of care
provided to patients [8]. Given that guidelines are
mostly disease-oriented, they have been the subject of
much criticism in primary care literature, partly due to
potential conflicting recommendations when implement-
ing those guidelines with patients presenting multiple
concurrent chronic conditions [9-12]. This leads to the
extended use of physician’s own clinical experience and
patients’ views on treatment choice instead of national
guidelines recommendations [13].* Correspondence: Martin.Fortin@USherbrooke.ca
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A tool recently developed by Boyd and colleagues [14]
allowed us to evaluate the applicability of guidelines on
chronic diseases for the treatment of subjects with
comorbidity (the term comorbidity replaces multimor-
bidity when the focus is on one specific index disease)
[15]. This instrument assesses whether guidelines
address treatment for people with several comorbid con-
ditions, as well as patient-centered aspects such as
patient preferences and quality of life. Canadian guide-
lines for chronic diseases have never been evaluated this
way. We examined the quality and the relevance of
Canadian clinical guidelines for patients with comorbid-
ity for selected chronic diseases.
Methods
This is a descriptive study based on a literature review
and the critical appraisal of clinical guidelines. We initi-
ally selected chronic medical conditions according to
their prevalence, complexity of treatment, and pertinence
to primary care. The selected conditions were: dyslipide-
mia, chronic impaired renal function, anxiety, heart fail-
ure, coagulopathy, obesity, atrial fibrillation, glaucoma,
peripheral arterial disease, chronic obstructive pulmonary
disease (COPD), asthma, osteoporosis, rheumatoid
arthritis, type II diabetes, dementia, high blood pressure,
hypothyroidism, and depression. Recent Canadian clini-
cal guidelines (2004 - 2009) published in English or
French were selected. Guidelines were identified through
the Medline database using the Ovid search engine
("guideline” [publication type] or text word and “Canada”
or “Canadian” as text word combined with the corre-
sponding diseases with various spellings as MeSH terms).
We also explored several websites known to refer to
guidelines: Guidelines Advisory Committee (GAC),
Canadian Medical Association InfoBase, Canadian Task
Force on Preventive Health Care, Recommended Clinical
Practice Guidelines, Canadian Clinical Practice Guide-
line, Canadian Thoracic Society, Canadian Cardiovascu-
lar Society, College of Physicians of Quebec, Canadian
Ophthalmological Society and The Canadian Diabetes
Association. When more than one guideline had been
published by the same organization only the most recent
version was retained.
The study was carried out at the Family Medicine Unit
of the Centre de santé et de services sociaux de Chicou-
timi and provided an opportunity for five family medicine
residents to complete their mandatory research training
under the guidance and supervision of the principal
investigator (MF).
To assess the relevance of the guidelines for the care of
patients with multiple chronic diseases, we adapted a 14-
item tool developed by Boyd and colleagues [14] and
expanded it to 17 by adding three items related to medica-
tion. This instrument, of relatively recent introduction, is
the only one available for this purpose. Boyd et al.’s tool is
a checklist in which each item is scored as “yes” or “no”.
The two principal measurement properties of this instru-
ment of interest to us are its content validity and interrater
reliability. Content validity is a qualitative assessment that
concerns the extent to which the measure includes all
relevant items. It was judged to be adequate by the develo-
pers of the tool [14] and by others having used it [15]. We
improved its comprehensiveness with the addition of
items related to medication. Regarding interrater reliabil-
ity, the agreement between two reviewers scoring the dif-
ferent items ranged from good to excellent [15]. In this
study consensus was reached among independent evalua-
tors. The instrument assesses if guidelines address treat-
ment for older people and for people with several
comorbid conditions, as well as patient-centred aspects
such as patient preferences and quality of life. A total
score was determined for each guideline for comparison
purposes.
Guidelines quality was assessed using the Appraisal of
Guidelines Research and Evaluation (AGREE) instrument
[16]. This instrument comprises 23 items covering six
domains. Agreement with the statement for each item is
scored on a Likert scale from 1 (complete disagreement)
to 4 (complete agreement). This instrument was validated
and its reliability is good (Cronbach’s alpha 0.64-0.88). A
detailed description of the properties of the instrument
(reliability and validity) was reported elsewhere [17]. It
should be scored by at least two evaluators. Domain
scores can be calculated by summing up all the scores
obtained for each individual item in a domain and by
standardizing the total as a percentage of the maximum
possible score for that domain.
The scoring of the two instruments was initially stan-
dardized in two steps by five evaluators. First, one guide-
line (anticoagulant therapy) was discussed and analyzed
jointly and consensus was reached for each item. Then,
two guidelines (hypertension and anxiety) were read and
appraised by the five evaluators independently before
results were compared. Differences in rating were
resolved by consensus. Thereafter, pairs of evaluators
were formed randomly to appraise each guide according
to AGREE and Boyd and colleagues’ modified instru-
ment. Each evaluator appraised the guidelines indepen-
dently. A consensus was reached after discussion on
divergent items.
Results
Sixteen Canadian guidelines were selected and appraised
[18-33]. Hypothyroidism and depression were removed
from the original list since we could not find guidelines
for the timeframe of the study (2004 - 2009). Table 1
shows the relevance of Canadian clinical guidelines for
the treatment of patients with multiple conditions. Nine
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guidelines (56.2%) addressed treatment for patients with
multiple chronic conditions but only three (18.8%)
addressed the issue for older patients. Fifteen guidelines
(93.8%) included specific recommendations for patients
with one comorbid condition; however, only three guide-
lines (18.8%) addressed specific recommendations for
patients with two comorbid conditions and only one
(chronic kidney disease) for more than two concurrent
comorbid conditions. All guidelines discussed medication
side effects, but only 10 (62.5%) discussed possible medi-
cation interactions related to comorbidities. Table 2
shows the performance of each Canadian guideline
according to Boyd and colleagues’ criteria. The guidelines
on chronic impaired renal function, heart failure, diabetes
mellitus and dementia had the best performance scores,
whereas the guidelines on atrial fibrillation and rheuma-
toid arthritis had the lowest.
The individual standardized AGREE domain scores
and mean scores are shown in Table 3. Scope and Pur-
pose and Clarity and Presentation obtained the highest
and second highest mean scores, respectively. Rigor of
Development and Editorial Independence were good
although the latter showed much variability. The Stake-
holder Involvement and Applicability domains obtained
the lowest scores. Five guidelines showed good quality
(score above 60%) in all domains: Chronic Impaired
Renal Function, Obesity, COPD, Diabetes Mellitus and
Glaucoma, the last two getting the highest marks.
Discussion
Although 56.2% of the guidelines addressed the treat-
ment of patients with multiple comorbid conditions, only
a minority (18.8%) provided specific treatment recom-
mendations for patients with two other conditions and
even less for those with more than two comorbid condi-
tions. This does not reflect the reality of primary care
where there is a very high prevalence of multimorbidity
[3-5]. These results are similar to an Australian study
reporting that 53% of 17 guidelines addressed treatment
for patients with multiple comorbid conditions [15]. One
can argue that due to the diversity of chronic diseases
seen in primary care, one cannot account for all possible
combinations and adjust guidelines accordingly. Chances
are that the evidence to support such recommendations
would be weak or absent as randomized control trials
often exclude patients with comorbidity or fail to
describe the morbidity burden of their participants in
published reports [34]. Of particular concern is the fact
that the issue of multiple comorbid conditions is rarely
discussed for older patients in the Canadian guidelines
Table 1 Relevance of Canadian clinical guidelines for the




Guideline addressed treatment for older patients 8 (50)
Guideline addressed treatment for patients with
multiple comorbid conditions
9 (56.2)
Guideline addressed treatment for older patients
with multiple comorbid conditions
3 (18.8)
Quality of evidence
Quality of evidence discussed for older patients 9 (56.2)
Quality of evidence discussed for patients with
multiple comorbid conditions
12 (75.0)




Specific recommendations for patients with one
comorbid condition
15 (93.8)
Specific recommendations for patients with two
comorbid conditions
3 (18.8)
Specific recommendations for patients with
more than two comorbid conditions
1 (6.2)
Burden of treatment
Time needed to treat to benefit from treatment
in the context of life expectancy discussed
9 (56.2)
Guideline discussed burden of comprehensive
treatment on patients or caregivers
6 (37.5)
Guideline discussed patients’ financial burden 4 (25)
Guideline discussed patients’ quality of life 13 (81.2)
Patient preferences
Guideline discussed patients’ preferences 9 (56.2)
Medication
Guideline discussed medications’ side effects 16 (100)
Guideline is adapted to possible medications’
side effects
12 (75)
Guideline discussed possible medications’
interactions related to comorbidities
10 (62.5)
Table 2 Guidelines performance according to Boyd and
colleagues’ modified criteria
Number of criteria satisfied (%)
Dyslipidemia,[18] 8 (47)
Chronic impaired renal function[19] 11 (65)
Heart failure[20] 13 (76)
Anticoagulant therapy[21] 7 (41)
Obesity[22] 7 (41)
Atrial fibrillation[23] 6 (35)
Peripheral arterial disease[24] 9 (53)
COPD[25] 9 (53)
Osteoporosis[26] 9 (53)
Rheumatoid arthritis 5 (29)
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despite the strong association between aging and the pre-
sence of multiple chronic conditions [3-5]. This situation
is not surprising considering the reliance on randomized
control trials (RCTs) that have excluded patients with
comorbidities in the development of evidence-based
guidelines [34]. This calls for a dramatic shift in clinical
research towards more pragmatic trials to generate evi-
dence and a greater implication of the primary care sec-
tor in the research process. Research on new models of
care for more complex patients and implying interdisci-
plinary collaboration is promising but thus far, publica-
tions are scarce [35]. A relatively low coverage of burden
of treatment and patient preferences is also an indication
of the lack of focus on the patient’s perspective in Cana-
dian guidelines on chronic diseases. This is in line with
the disease-oriented paradigm from which the guidelines
arise. This is a concrete example of the misconceptualiza-
tion of the primary care role from the guidelines develo-
per perspective as reported by Starfield [9]. All guidelines
discussed medication side effects, with 62.5% of them dis-
cussing, to some extent, possible interactions related to
comorbidity. However, in most cases, the discussion was
superficial and limited to a few warnings. Both drug-drug
and drug-disease interactions are possible in patients
with comorbidities [36]. Appropriate management of
comorbidity should be included in guidelines for particu-
lar diseases [37]. Most guidelines failed to discuss the
burden of comprehensive treatment on patients or care-
givers. This is especially of concern for older patients
with multimorbidity who may find it very difficult to
adopt the regimen issued from the many guidelines that
would apply to them [14]. Summing up the score for
individual items for each guideline from Boyd and collea-
gues’ instrument resulted in an overall score allowing for
comparisons between guidelines. Guidelines for diabetes
mellitus performed the best. This is reassuring as dia-
betes is associated with many chronic diseases and com-
plications. However, a low score for atrial fibrillation is
especially of concern, as the treatment of this condition
will interfere with many other conditions.
The quality of the guidelines evaluated in this study
was good to very good in four out of the six domains
measured by the AGREE instrument. This evaluation is
necessary to ensure that the guidelines are of good qual-
ity according to Boyd and colleagues ’ criteria. The
domains with lower scores were: Stakeholder Involve-
ment and Applicability. Guidelines devoted to improved
quality of primary care would certainly benefit from a
strong partnership with primary care providers in
charge of applying the guidelines and this is especially
of concern due to the high prevalence of chronic dis-
eases in this setting. The low scores of those two criteria
call for a more pragmatic way of elaborating and formu-
lating guidelines in order to better fit the needs of tar-
geted users. There is no use for a guideline if its
implementation into practice is not facilitated and does
not entail a shift of paradigm from the more disease-
oriented guideline developers to the more patient-
oriented users [38,39]. The Scope and Purpose, and
Clarity and Presentation domains obtained very good
scores; this, along with the good scores of the Rigor of
Development domain, speaks well to the scientific qual-
ity and validity of guidelines that is the hallmark of
Canadian research.











Dyslipidemia[18] 83.3 33.3 81.0 100 44.4 100
Chronic impaired renal
function[19]
100 66.6 78.6 100 72.2 100
Heart failure[20] 77.8 62.5 71.4 87.5 38.8 100
Anticoagulant therapy[21] 100 62.5 42.9 100 75 62.3
Obesity[22] 100 62.5 100 91.7 83.3 91.7
Atrial fibrillation[23] 88.9 25.0 64.3 71.0 22.2 25.0
Peripheral arterial disease
[24]
94.4 25.3 78.6 100 33.3 50.0
COPD[25] 94.4 75.0 78.6 100 66.7 66.7
Osteoporosis[26] 100 25.0 71.4 75.0 33.3 33.3
Rheumatoid arthritis 88.9 25.0 47.6 58.3 22.2 41.7
Diabetes mellitus[28] 88.9 83.3 100 100 88.9 100
Asthma[29] 88.9 66.7 85.7 91.7 16.7 66.7
Dementia[30] 100 79.2 90.5 58.3 11.1 100
Glaucoma[31] 100 66.7 100 100 77.8 100
Anxiety[32] 91.7 68.3 85.6 100 33.3 66.7
Hypertension[33] 91.7 55.0 97.1 95.0 48.9 86.7
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This study has limitations. Although our selection cri-
teria allowed us to include a variety of important medi-
cal conditions, our results cannot be generalized to
other Canadian guidelines not included in this study.
Another limitation is that Boyd and colleagues’ instru-
ment is a relatively new tool; this may raise questions
about its use in evaluating guidelines. The AGREE
instrument provides a well validated framework for the
assessment of the quality of guidelines. However, ratings
can be influenced by the reviewer’s background knowl-
edge of the guideline subject. We tried to reduce this
bias by distributing guidelines randomly among the
reviewers.
Conclusion
Our results show that the quality of Canadian guidelines
is good, particularly in their scope and purpose, as well
as in clarity and presentation. However, their relevance
for patients with more than two comorbid conditions is
very limited and there is room for improvement in this
respect. It may be the reflection of some disconnection
between guideline developers and primary care provi-
ders. Clinical judgment is still necessary to adjust guide-
line recommendations for patients with comorbidity.
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